Rilvegostomig + Bevacizumab w/or w/o Tremelimumab as First Line treatment in advanced Hepatocellular Carcinoma

A Phase III, Randomized, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Disease Types: Hepatocellular

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase III, Randomized, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma 

For More Information:

https://clinicaltrials.gov/study/NCT06921785?term=Rilvegostomig%20&viewType=Card&cond=Hepatocellular%20Carcinoma&rank=1